Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung Biologics (207940) – DS Investment & Securities | Plant 5 Revenue Contribution · US Plant Acquisition · Plant 6 Groundbreaking / 2026-04-23 Research
  • [Research] ABL Bio (298380) – Kiwoom Securities | ABL301 Deprioritization · ABL001 Valuation · Grabody B Validity / 2026-02-02 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | HBM4 · Product Mix · LTA / 2026-07-30 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | LTA · Earnings Visibility · Shareholder Returns / 2026-08-03 Research
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Commodity DRAM · ASP Resilience · Earnings Growth / 2026-07-29 Research
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | Silicon Capacitor · ASP Expansion · Valuation Re-rating / 2026-05-26 Research
  • [Research] Samsung SDI (006400) – Mirae Asset | North American ESS · European LFP Orders · Market Share Expansion / 2026-08-13 Research
  • [Research] Samsung Biologics (207940) – Shinhan Securities | Capacity Expansion · Peptide Entry · Guidance Upgrade / 2026-07-24 Research

[Research] SK hynix (000660 / SKHY) – Shinhan | DRAM Supply Shortage · Supplier Pricing Power · HBM3E / 2026-01-05

Posted on January 5, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Shinhan Securities

Analyst : Hyungtae Kim (RA: Hyesus Song)

Investment Rating : BUY (Maintained)

Target Price : 860,000 KRW (Raised)

Core Momentum : Intensifying commodity DRAM supply shortages and low channel inventories are expected to sustain supplier pricing power, while an extended HBM3E cycle and rising ASIC adoption support continued earnings growth.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price: 860,000 KRW (Based on Target P/B 3.2x applied to 2026F BPS of 268,240 KRW, Raised)
  • Investment Rating: BUY (Maintained)
  • 2026F Financial Outlook: Revenue 152.14 trillion KRW, Operating Profit 91.79 trillion KRW, Net Income 77.32 trillion KRW
  • Valuation Multiples: PER 6.4x, PBR 2.5x, EV/EBITDA 4.1x, ROE 49.3% (Based on 2026F)

🚀 2. [Market Opportunities & Business Outlook]

  • 4Q25 Preview: Revenue is expected to reach 30.8 trillion KRW (+25.9% QoQ) and operating profit 16.1 trillion KRW (+41.7% QoQ), beating consensus estimates (Revenue 29.3 trillion KRW, OP 15.1 trillion KRW). Divisional operating profit is estimated at 15.5 trillion KRW for DRAM and 0.7 trillion KRW for NAND. Estimated B/G for DRAM/NAND stood at +0.4%/+2.7%, and ASP growth at +19%/+13.6%, beating prior expectations. DRAM operating margins are projected to exceed 60% driven by accelerated generic DRAM profitability improvements.
  • Industry & LTA Dynamics: Intensified generic DRAM supply shortages drove ASP growth estimates up by an additional 10%p. Front-end channel inventories remain low. Amid ongoing discussions for generic memory Long-Term Agreements (LTAs), pricing power remains heavily tilted toward suppliers.
  • Growth Drivers: Prolongation of the HBM3E cycle and rising ASIC adoption rates are expected to sustain an upward trajectory. SK hynix is projected to maintain its HBM competitive edge backed by superior cost efficiencies compared to peers.

📝 Editor’s Comment (Perspective)

The analyst views SK hynix as an enterprise capturing explosive earnings growth within a supplier-centric market forged by capacity constraints and robust demand, leveraging superior cost competitiveness. The analyst highlights earnings level-ups and supplier pricing power.

To verify this investment thesis, one should track whether 4Q25 results hit the projected revenue of 30.8 trillion KRW and operating profit of 16.1 trillion KRW with expanded margins, if supplier-driven LTA contracts are successfully formalized, and how the extended HBM3E cycle and rising ASIC adoption translate into financial performance. These indicators can be monitored through upcoming quarterly reports and regulatory filings via DART.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Daishin | HBM4 · Memory Supply Shortage · Shareholder Returns / 2026-01-02
Next Post: [Research] Samsung Biologics (207940) – Hana Securities | Post-Spinoff Profitability · Record KRW 6.8T Orders · Plant 6 Groundbreaking Visibility / 2026-01-07

Related Posts

  • [Research] Samsung SDI (006400) – Hana Securities | Stepwise Loss Reduction · Strong ESS BBU Shipments · 4Q26 Turnaround / 2026-02-03 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Supply Constraints · Earnings Surge / 2026-05-11 Research
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | AI MLCC Shortage · FC-BGA Margin Expansion · Earnings Direction / 2026-07-31 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Dual Growth Engines · 2Q26 OPM Ramp-up · Substrate CapEx Doubling / 2026-05-04 Research
  • [Research] Samsung SDI (006400) – Hana Securities | SDC Stake Monetization Pursuit · Up to KRW 11T Liquidity · Valuation Multiples Re-rating / 2026-02-20 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | SDC Stake Monetization · Tesla ESS Business Expansion · Earnings Trough / 2026-02-20 Research
  • [Research] Samsung SDI (006400) – IBK Securities | Accelerating North American ESS Conversions · FY26 AMPC KRW 359B · 4Q In Line / 2026-02-03 Research
  • [Research] Samsung Electro-Mechanics (009150) – SK Securities | Global Tier-1 Multiples · Passive-Substrate Synergy · Embedded & Si-Cap / 2026-05-26 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | BBU Momentum · Hungarian Utilization Rebound · 2026 Operating Profit Turnaround / 2026-03-18 Research
  • [Research] Samsung Biologics (207940) – Daishin Securities | Peptide Market Entry · Global Footprint Expansion · Modality Diversification / 2026-07-21 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Legacy Memory Pricing · LTA · ADR / 2026-02-23 Research
  • [Research] Alteogen (196170) – Shinhan Securities | 2 Out-Licensing Deals in Q1 · Biogen Deal Analysis · Major Catalysts Ahead from April / 2026-03-27 Research
  • [IR] Samsung Electronics (005930) – Q1 2024 Earnings Presentation / 2024-04-30 IR Room
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Commencing Customer T ESS Business (Estimated) · SDC Asset Utilization · Valuation Gap Narrowing / 2026-02-03 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme